Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trius Confident After Phase II Results Against Skin Infections That Include MRSA

This article was originally published in The Pink Sheet Daily

Executive Summary

Torezolid, a second generation oxazolidinone antibiotic, is set to enter Phase III trials in early 2010 with unambiguous regulatory guidance, CEO says.

You may also be interested in...



Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints

Tedizolid, a next-generation antibiotic from the same class as Pfizer’s Zyvox, has met all complicated skin infection endpoints for both a U.S. and European filing, and Trius plans submissions in second half 2013 and first half 2014, respectively. European partnering talks, meanwhile, have gained new intensity.

Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance

Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area

Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance

Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel